Biogaran
Biogaran is a French pharmaceutical laboratory, founded in 1996 and owned by BC Partners, that manufactures and distributes generic prescription medications, OTC products (Biogaran Conseil), medical devices, cosmetics, and dietary supplements through France's nationwide pharmacy network to patients, pharmacists, and prescribers.
- Company typePrivate
- Founded1996
- HeadquartersColombes, France
- Headcount101–250
- GTM typeB2C
- OfferingHardware or Manufacturing
What Biogaran does
Biogaran is a French pharmaceutical laboratory founded in 1996, headquartered in Colombes, France, and currently owned by British private equity firm BC Partners following a 2025 divestiture from Servier. The company specializes in generic prescription medications, distributed nationally through French pharmacies under partial or full reimbursement by the French social security system. Its product portfolio spans five primary categories: generic prescription medications, OTC self-care products marketed under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. The company also runs adjunct patient-support initiatives such as Mon Bracelet Biogaran (adherence), Mon Urgence Pilule, Biog'Stories, and oncology and aging-at-home programs, plus content publishing through Le Mag Biogaran.
Biogaran's business model is built on volume-driven sales of generics and OTC products through the nationwide French pharmacy channel, with pharmacists serving as both distribution and counseling touchpoints. Marketing is multi-channel (TV, social platforms, content, experiential events), and consumer-facing brand equity has been recognized via the 'marque préférée des Français' designation. Pricing is governed by French reimbursement frameworks for prescription products and out-of-pocket purchase for OTC items; pricing is not publicly disclosed. The company employs 101-250 people and reports a 30-year operational history.
In 2026, Biogaran extended beyond small-molecule generics into the ophthalmology biosimilar segment via a co-commercialization partnership with Sandoz and Lupin for Ranluspec (ranibizumab biosimilar) in France. The company has no disclosed AI/ML, APIs, or technology platform beyond manufacturing and formulation capabilities, and relies on regulatory compliance, brand, and pharmacy distribution as its principal assets.
Biogaran firmographics
Firmographics- Name
- Biogaran
- Legal name
- Biogaran
- Website
- https://biogaran.fr
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Biogaran is a French pharmaceutical laboratory, founded in 1996 and owned by BC Partners, that manufactures and distributes generic prescription medications, OTC products (Biogaran Conseil), medical devices, cosmetics, and dietary supplements through France's nationwide pharmacy network to patients, pharmacists, and prescribers.
- Ownership category
- akta.pro rank
Biogaran industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)
- akta.pro secondary industries
- Biologics & Biosimilars Distributors (HLAIAJAH), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where Biogaran is headquartered
LocationHeadquarters
- HQ city
- Colombes
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Biogaran business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Others
Revenue model
- Generic Medications: Sale of generic prescription medications through pharmacy networks across France
- OTC Products (Biogaran Conseil): Over-the-counter medications and self-medication products sold without prescription through pharmacies
- Health Content and Services: Patient education content and digital health services including health articles, vaccination information, and wellness guidance
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription generic medications |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Biogaran product offering
Product offeringCore offering
Biogaran is a French pharmaceutical laboratory that manufactures and distributes generic prescription medications, over-the-counter (OTC) health products under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. Products are sold primarily through the French pharmacy network, with partial or full reimbursement under French social security, complemented by patient education content (Le Mag) and pharmacovigilance services.
Product overview
Biogaran is a French pharmaceutical laboratory specializing in generic medications and health products since 1996. The company operates a diversified portfolio organized around five product categories: generic prescription medications (Médicaments), medical devices (Dispositifs Médicaux), cosmetics (Cosmétiques), dietary supplements (Compléments Alimentaires), and over-the-counter products under the Biogaran Conseil sub-brand. Beyond pharmaceutical products, Biogaran offers patient support initiatives including Mon Bracelet Biogaran (treatment adherence tool), Mon Urgence Pilule (emergency contraception info), Biog'Stories (patient storytelling), and Contre le Cancer On Fait Equipe (cancer support). The company also provides health education through Le Mag and maintains pharmacovigilance services. Recently, Biogaran expanded into biosimilars through a partnership with Lupin and Sandoz for the distribution of Ranluspec in France.
Differentiator
Problem solved
Functional benefit
Brands
- Biogaran Conseil: Over-the-counter (OTC) medication and health product line sold without prescription, featuring packaging campaigns and pharmacy partnerships.
Quantifiable outcome
- 88% of respondents in Ifop study have purchased OTC medications
- +1 more outcomes
Companies that use Biogaran
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Biogaran technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Biogaran partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- SandozcoreSandoz handles commercialization of Lupin's biosimilar Ranluspec across the European Union excluding Germany. Biogaran co-commercializes the product in France, strengthening distribution capabilities for this ophthalmology biosimilar treatment.
- SandozcoreDistribution partnership where Sandoz commercializes Ranluspec (biosimilar ranibizumab) across EU excluding Germany, with Biogaran handling distribution in France for eye condition treatments.
Scale indicators2 records
Recent moves7 records
Expansion highlights5 records
Biogaran competitors and assessment
Company assessmentDirect peers
- Stada Arzneimittel: Stada is a European-focused generics and consumer healthcare company with a similar OTC + generics dual model. Comparable business model and go-to-market through European pharmacy networks; previously PE-owned, mirroring Biogaran's ownership profile.
- Arrow Génériques (Aurobindo): Arrow Génériques is the European generics arm of Aurobindo and a direct France-market competitor in generic prescriptions through pharmacy distribution. Closely comparable on therapeutic coverage and pharmacy-channel model.
- Krka: Krka is a Slovenian generics manufacturer with significant Western European sales. Comparable on generic prescription drugs, OTC consumer health products, and pharmacy-channel distribution model across continental Europe.
- Almus (Accord Healthcare): Almus is the generics brand of Accord Healthcare, a major European generic player competing in pharmacy channels across France. Comparable on generics portfolio breadth and pharmacy-channel go-to-market.
- Sandoz: Sandoz is the global leader in generic pharmaceuticals and biosimilars, spun out of Novartis. Directly comparable as a generic and biosimilar manufacturer/distributor; Biogaran actually partners with Sandoz to co-commercialize Ranluspec in France, confirming channel and portfolio overlap.
- EG Labo (Stada group): EG Labo is the French generics subsidiary of Stada and a head-to-head competitor in the French pharmacy generics market. Closely comparable on domestic French market positioning, generics portfolio, and pharmacy-distribution model.
- Teva Pharmaceutical Industries: Teva is one of the world's largest generic drug manufacturers with a strong European footprint. Directly comparable on generics manufacturing, OTC portfolio, and biosimilars; competes head-to-head in France and broader Europe.
- Viatris (formerly Mylan): Viatris is a global generics and specialty pharma company with deep European presence. Comparable on generic prescription and OTC distribution, broad therapeutic coverage, and biosimilar ambitions; competes with Biogaran across French pharmacy channel.
- Zentiva: Zentiva is a European generics manufacturer headquartered in Prague with strong presence in France. Closely comparable as a European-branded generics specialist serving pharmacy channels with a similar portfolio breadth and reimbursement-driven model.
Broad incumbents
- Laboratoires Servier: Servier is Biogaran's former parent and a major French pharmaceutical group with branded specialty drugs. Comparable as a French pharma operator with pharmacy-channel reach; broader portfolio (innovative branded drugs) but historically the same corporate parent.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks1 record
Key highlights7 records
Customer concentration
Biogaran social profiles
Digital presenceBiogaran financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biogaran leadership team
Management profileNumber of profiles
Biogaran funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biogaran M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biogaran
What does Biogaran do?
Biogaran is a French pharmaceutical laboratory that manufactures and distributes generic prescription medications, over-the-counter (OTC) health products under the Biogaran Conseil sub-brand, medical devices, cosmetics, and dietary supplements. Products are sold primarily through the French pharmacy network, with partial or full reimbursement under French social security, complemented by patient education content (Le Mag) and pharmacovigilance services.
Is Biogaran a public or private company?
Biogaran is a private company. It is classified as private equity controlled and is currently operating.
When was Biogaran founded?
Biogaran was founded in 1996. It employs 101 to 250 people.
Where is Biogaran based?
Biogaran is headquartered in Colombes, France, in the Europe region.
How does Biogaran make money?
Three revenue lines are on record. Generic Medications are the primary driver. The others are OTC Products (Biogaran Conseil) and health Content and Services.
Who are Biogaran's main competitors?
Direct peers on record are Stada Arzneimittel, Arrow Génériques (Aurobindo), Krka, Almus (Accord Healthcare), Sandoz, EG Labo (Stada group), Teva Pharmaceutical Industries, Viatris (formerly Mylan) and Zentiva. Laboratoires Servier is listed as a broad incumbent.
Does Biogaran have an API?
No public API is recorded for Biogaran.
What industry is Biogaran in?
Biogaran's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is CRAOAHAB, OTC Medicines & Consumer Health Products Distribution, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 325412 and its SIC code is 2834.